Bayer (BAYN) Given a €125.00 Price Target by Goldman Sachs Group Analysts

Goldman Sachs Group set a €125.00 ($154.32) price target on Bayer (FRA:BAYN) in a research report released on Tuesday, January 23rd. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other equities analysts have also weighed in on BAYN. Commerzbank set a €124.00 ($153.09) target price on shares of Bayer and gave the company a buy rating in a report on Friday, October 6th. Citigroup set a €130.00 ($160.49) target price on shares of Bayer and gave the company a buy rating in a report on Thursday, October 5th. Sanford C. Bernstein set a €129.00 ($159.26) target price on shares of Bayer and gave the company a buy rating in a report on Friday, October 13th. Warburg Research set a €121.00 ($149.38) target price on shares of Bayer and gave the company a neutral rating in a report on Thursday, October 5th. Finally, Baader Bank set a €140.00 ($172.84) target price on shares of Bayer and gave the company a buy rating in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company’s stock. Bayer has an average rating of Buy and an average target price of €121.71 ($150.26).

Shares of Bayer (BAYN) traded up €0.86 ($1.06) during midday trading on Tuesday, reaching €97.81 ($120.75). 3,407,652 shares of the company traded hands. The stock has a market cap of $80,720.00 and a PE ratio of 23.12. Bayer has a one year low of €93.30 ($115.19) and a one year high of €123.82 ($152.86).

WARNING: “Bayer (BAYN) Given a €125.00 Price Target by Goldman Sachs Group Analysts” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/14/bayer-bayn-given-a-125-00-price-target-at-goldman-sachs-group-2.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply